Heidi Health vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
Australian AI clinical documentation platform. Used by Monash Health (1.6M patients). $96.6M raised ($65M Series B at $465M valuation). Founded 2019, Melbourne.
About
Heidi Health was founded in 2019 in Melbourne, Australia by Dr. Thomas Kelly and Ryan Wright to eliminate the administrative burden of clinical documentation for healthcare providers. Clinicians spend 30–50% of working hours on documentation — typing notes, generating referral letters, completing forms — time that could otherwise go to patient care. Heidi built an ambient AI documentation platform that listens to patient consultations, transcribes in real time, and automatically generates structured clinical notes and referral letters tailored to each clinician's specialty.\n\nThe platform integrates with major EHR systems to push completed notes directly into patient charts, eliminating copy-paste friction. The AI engine supports general practice, specialist medicine, allied health, and nursing, and learns each clinician's personal documentation style over time to reduce editing effort. Heidi is deployed at Monash Health in Victoria, one of Australia's largest public health networks serving 1.6 million patients, as a flagship enterprise reference deployment.\n\nHeidi Health has raised $96.6 million in total funding, including a $65 million Series B at a $465 million valuation. The company is one of the fastest-growing clinical documentation AI platforms in Australia and is expanding internationally. As health systems globally address clinician burnout driven by documentation load, ambient AI documentation is emerging as a high-ROI technology investment, positioning Heidi Health alongside US-based competitors including Nuance DAX and Suki.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.